Mental Health & GLP-1
Patients consistently report quieter "food noise" within 1-2 weeks of starting a GLP-1. The mood literature is more mixed — most users see no change, a minority report low mood, and a small fraction experience improvement in binge-eating-related distress.
The constant intrusive thoughts about food — what to eat, when, planning meals — quiet substantially on GLP-1s. Surveys put the effect at 80%+ of users. For binge eating disorder, semaglutide reduces frequency in small open-label trials; tirzepatide data is emerging.
Most users report no change in baseline mood. A minority (3-7%) report low mood during dose escalations — sometimes from rapid weight loss disrupting eating-as-coping, sometimes from sleep disturbance, sometimes pharmacologic. Stable doses generally normalize. Pre-existing major depression should be flagged to the prescriber.
GLP-1s should be used cautiously in patients with a history of anorexia, bulimia, or restrictive eating. The medication exaggerates the appetite suppression that drives those disorders. Most prescribers screen for ED history; therapy continuity is essential during dose changes.
Recent large-scale EHR analyses (JAMA Psychiatry 2024) found no signal for new-onset depression or suicidality. A minority of patients (3-7%) report transient low mood during dose escalations. If you have a history of depression, share that with your prescriber before starting; dose changes should be paired with continued therapy or psychiatry follow-up.
Food noise describes intrusive, repetitive thoughts about food and eating — distinct from physical hunger. The vast majority of GLP-1 users (>80%) report a dramatic reduction within 1-2 weeks of starting. The mechanism likely involves GLP-1 receptors in brain reward pathways, not just gastric emptying.
Comparison includes consultation flow, formulary, and pricing.
See top-rated providers